# Tarsus Pharmaceuticals, Inc. (TARS) — capital_raise/private_placement [completed]
Source: SEC API (secapi.ai) · situation sit_cce57e7428c6c20344f9 · retrieved 2026-08-12T07:23:51.161Z

## Overview
Tarsus Pharmaceuticals applies proven science and new technology to revolutionize treatment for patients, starting with eye care; XDEMVY (lotilaner ophthalmic solution) is FDA-approved for Demodex blepharitis, and the company is developing TP-04 for ocular rosacea, TP-05 for Lyme disease prevention, and IRX-101 as an ocular antiseptic.

Tarsus Pharmaceuticals announced a pending acquisition of Alkeus Pharmaceuticals to expand its retina pipeline with ALK-001, an investigational once-daily oral therapy in Phase 3 development for Stargardt disease, an inherited retinal disease affecting more than 36,000 patients in the United States. Concurrently, Tarsus priced a $125 million private placement financing that included participation from top-tier funds and several existing Alkeus Pharmaceuticals investors.

## Terms
- Counterparty: Alkeus Pharmaceuticals · Deal value: $125.0M · Consideration: cash

## Key dates
- Completed 2026-08-06

## Timeline
- 2026-08-06 · 8-K (0001819790-26-000063): 8-K - Tarsus Pharmaceuticals, Inc. — *Tarsus Pharmaceuticals applies proven science and new technology to revolutionize treatment for patients, starting with eye care; XDEMVY (lotilaner ophthalmic solution) is FDA-approved for Demodex blepharitis, and the company is developing TP-04 for ocular rosacea, TP-05 for Lyme disease prevention, and IRX-101 as an ocular antiseptic.* Tarsus Pharmaceuticals announced a pending acquisition of Alkeus Pharmaceuticals to expand its retina pipeline with ALK-001, an investigational once-daily oral therapy in Phase 3 development for Stargardt disease, an inherited retinal disease affecting more than 36,000 patients in the United States. Concurrently, Tarsus priced a $125 million private placement financing that included participation from top-tier funds and several existing Alkeus Pharmaceuticals investors.
  https://www.sec.gov/Archives/edgar/data/1819790/0001819790-26-000063.txt

## Citations
- 0001819790-26-000063 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000181979026000063